Surgery Partners (NASDAQ:SGRY) Downgraded to “Buy” at ValuEngine

ValuEngine downgraded shares of Surgery Partners (NASDAQ:SGRY) from a strong-buy rating to a buy rating in a research note released on Thursday, ValuEngine reports.

Several other equities analysts have also recently weighed in on the stock. Royal Bank of Canada lowered their price objective on shares of Surgery Partners from $19.00 to $14.00 and set an outperform rating on the stock in a research report on Tuesday, March 24th. UBS Group lifted their price objective on shares of Surgery Partners from $12.00 to $19.00 and gave the stock a neutral rating in a research report on Thursday, February 20th. Zacks Investment Research cut shares of Surgery Partners from a buy rating to a hold rating in a research report on Wednesday, February 5th. Citigroup lifted their price objective on shares of Surgery Partners from $13.00 to $20.00 and gave the stock a buy rating in a research report on Tuesday, December 10th. Finally, BidaskClub upgraded shares of Surgery Partners from a strong sell rating to a sell rating in a research report on Thursday, March 26th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $16.67.

Shares of NASDAQ SGRY traded up $0.41 during trading on Thursday, hitting $5.21. The company had a trading volume of 493,085 shares, compared to its average volume of 578,395. The company has a market cap of $256.80 million, a P/E ratio of -2.30 and a beta of 2.88. Surgery Partners has a 52 week low of $4.00 and a 52 week high of $19.74. The business’s 50-day moving average is $11.72 and its 200 day moving average is $12.42. The company has a debt-to-equity ratio of 2.57, a quick ratio of 1.20 and a current ratio of 1.32.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.02). Surgery Partners had a negative net margin of 4.03% and a negative return on equity of 2.42%. The company had revenue of $517.20 million during the quarter, compared to the consensus estimate of $504.08 million. On average, research analysts expect that Surgery Partners will post -0.78 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. State Street Corp grew its holdings in shares of Surgery Partners by 20.0% during the 3rd quarter. State Street Corp now owns 448,935 shares of the company’s stock valued at $3,315,000 after acquiring an additional 74,930 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Surgery Partners during the 4th quarter valued at $163,000. Barclays PLC grew its holdings in shares of Surgery Partners by 21.6% during the 3rd quarter. Barclays PLC now owns 19,294 shares of the company’s stock valued at $143,000 after acquiring an additional 3,432 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Surgery Partners by 96.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,758 shares of the company’s stock valued at $707,000 after acquiring an additional 46,891 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new position in shares of Surgery Partners during the 4th quarter valued at $1,476,000. Institutional investors and hedge funds own 92.36% of the company’s stock.

Surgery Partners Company Profile

Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.

Featured Article: Insider Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.